Veloce BioPharma LLC has recently announced the rapid viricidal efficacy of its Halodine® Antiseptics against the virus that causes the COVID-19 disease, SARS-CoV-2.
Halodine®, developed by collaborating with the leading clinicians for repeated nasal and oral administration, is a proprietary iodopovidone (povidone-iodine) antiseptic. From the experiments conducted with the IAR (Institute for Antiviral Research) at USU (Utah State University), a BSL3+ laboratory, these proprietary oral and nasal antiseptic preparations have been proven to rapidly inactivate the SARS-CoV-2. It is proven to be effective, even at as low as 1/20 dilutions of the commercially available solutions.
According to Ocean Ophthalmology Group’s Jesse Pelletier MD FACS, the study reveals the effectiveness of the non-toxic oral and nasal solution, which is the 1st iodine-based antiseptic to be proven effective against the virus. This efficacy for povidone-iodine solutions, safe for mucosa, will enable them to incorporate in the fight against the COVID-19 transmission reduction. He is leading the efforts to design the safe return-to-work protocols for ambulatory surgery centers and ophthalmology outpatient clinics. Oral rinses and nasal antisepsis can effectively reduce the risk of virus transmission.
Halodine® antiseptics are specifically developed for repeated, safe use against the high viral loads in the mouth and nose. These viral loads have high risks of transmission, especially in the healthcare settings. The main sources of coronavirus transmission are respiratory and nasal aerosols & droplets. These viral droplets and aerosols can remain infectious for over 3 hours. This aerosol transmission may be reduced, owing to the recently proven effectiveness of oral and nasal antiseptics.
Samuel Barone, MD, Veloce BioPharma’s Chief Medical Officer, has reportedly stated that continuous research efforts must be conducted to understand the behavior of the novel coronavirus. The Halodine® Antiseptic program is a result of years of working experience in ophthalmology and dermatology on the iodophor-based antiviral therapies. He further expressed the company’s excitement about the effective results that demonstrate the efficacy of this medication against the COVID-19 disease.